Market focus ViQi operates in data infrastructure and analytics for bioprocess development, offering AI imaging and cloud-based workflows to biopharma CDMOs, CROs, and labs. Sales opportunities exist in expanding collaborations with life sciences manufacturers seeking standardized, data-driven, regulated analysis to replace manual workflows.

Recent recognition Award wins at NIIMBL Technology Innovation and recognition for Technology Innovation Tank signal strong market validation and credibility. Leverage this for co-selling, case studies, and speaking engagements to open doors with potential clients and larger biopharma teams.

Strategic hires Addition of a Scientific Advisory Board and a seasoned CSO enhances credibility with scientific leadership. Position ViQi as a trusted partner for rigorous bioprocess analytics, enabling deals that require strong scientific oversight and regulatory-aligned practices.

Integrations edge Existing integration with Araceli's Endeavor system demonstrates interoperability with established phenotypic profiling platforms. Sales opportunities exist in cross-selling and integration-friendly pitches to labs using complementary tools seeking end-to-end automated analysis.

Growth potential Revenue tier indicates early-stage scale with 1–10 million in annual revenue and a 4 million funding backdrop. Target mid-to-large biopharma and CRO/CDMO partners pursuing scalable, reproducible analytics to accelerate development timelines and reduce turnaround times.